Effects of immunomodulators on the response induced by vaccines against autoimmune diseases

References

• Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008;41:123–132.
   PubMed Web of Science ®Google Scholar
• Doyle HA, Yang M-L, Raycroft MT, et al. Autoantigens: novel forms and presentation to the immune system. Autoimmunity. 2014;47:220–233.
   PubMed Web of Science ®Google Scholar
• Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis. 2015;3:151–155.
   Google Scholar
• Versini M, Jeandel PY, Bashi T, etet al. Unraveling the Hygiene Hypothesis of helminths and autoimmunity: origins, pathophysiology, and clinical applications. BMC Med. 2015;13:81.
   PubMed Web of Science ®Google Scholar
• Gause WC, Wynn TA, Allen JE. Th2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607–614.
   PubMed Web of Science ®Google Scholar
• Guimarães LE, Baker B, Perricone C, et al. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.
   PubMed Web of Science ®Google Scholar
• van der Laan JW, Gould S, Tanir JY. ILSI HESI Vaccines and Adjuvants Safety Project Committee. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine. 2015;33:1507–1514.
   PubMed Web of Science ®Google Scholar
• Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Investig Dermatol. 2005;125:629–637.
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira STLR. signaling pathways. Semin Immunol. 2004;16:3–9.
   PubMed Web of Science ®Google Scholar
• Bedoya SK, Lam B, Lau K, et al. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.
   PubMedGoogle Scholar
• Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13:668–677.
   PubMed Web of Science ®Google Scholar
• Jackson JA, Friberg IM, Little S, et al. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies?. Immunology. 2008;126:18–27.
   Web of Science ®Google Scholar
• Zaccone P, Cooke A. Vaccine against autoimmune disease: can helminths or their products provide a therapy? Curr Opin Immunol. 2013;25:418–423.
   PubMed Web of Science ®Google Scholar
• Araujo MI, Hoppe BS, Medeiros M, et al. Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Mem Inst Oswaldo Cruz. 2004;99(Suppl I):27–32.
   Web of Science ®Google Scholar
• Conrad ML, Renz H, Blaser K. Immunological approaches for tolerance induction in allergy. Curr Topics Microbiol Immunol. 2011;352:1–26.
   PubMed Web of Science ®Google Scholar
• Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol. 2014;5:365.
   PubMed Web of Science ®Google Scholar
• Mannie MD, Curtis AD. Tolerogenic vaccines for multiple sclerosis. Hum Vaccin Immunother. 2013;9:1032–1038.
   PubMed Web of Science ®Google Scholar
• Hussaarts L, Yazdanbakhsh M, Guigas B. Priming dendritic cells for Th2 polarization: lessons learned from helminths and implications for metabolic disorders. Front Immunol. 2014;5:499.
   PubMed Web of Science ®Google Scholar
• Okano M, Satoskar AR, Nishizaki K, et al. Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response. J Immunol. 2001;167:442–450.
   PubMed Web of Science ®Google Scholar
• Kuijk LM, van Die I. Worms to the rescue: can worm glycans protect from autoimmune diseases? IUBMBLife. 2010;62:303–312.
   PubMed Web of Science ®Google Scholar
• Clark JF. The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited. Mol Hum Reprod. 2014;20:185–199.
   PubMed Web of Science ®Google Scholar
• Hewitson JP, Grainger JR, Maizels RM. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol. 2009;167:1–11.
   PubMed Web of Science ®Google Scholar
• Rasko DA, Wang G, Monteiro MA, et al. Synthesis of mono- and di-fucosylated type I Lewis blood group antigens by Helicobacter pylori. Eur J Biochem. 2000;267:6059–6066.
   PubMedGoogle Scholar
• Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol. 2013;178:1721–1730.
   PubMed Web of Science ®Google Scholar
• Taghipour N, Aghadei HA, Haghighi A, et al. Potential treatment of inflammatory bowel disease: a review of helminths therapy. Gastroenterol Hepatol Bed Bench. 2014;7:9–16.
   PubMedGoogle Scholar
• Helmby H. Human helminth therapy to treat inflammatory disorders: where do we stand?. BMC Immunol. 2015;37:208–214.
   Google Scholar
• Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today. 2014;19:912–920.
   PubMed Web of Science ®Google Scholar
• Hirsch DL, Ponda P. Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther. 2014;4:1–11.
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Fordham SA, Bernard CCA, et al. DNA vaccines for the treatment of autoimmune diseases. Immunol Cell Biol. 1997;75:409–413.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Conover J, Bloom ET, et al. Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci. 1998;53A:B281–B286.
   Google Scholar
• Pawelec G, Lutsgarten J, Ruby C, et al. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother. 2009;58:1907–1908.
   PubMed Web of Science ®Google Scholar
• Garren H, Ruiz PJ, Watkins TA, et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity. 2001;15:15–22.
   PubMed Web of Science ®Google Scholar
• Blanchfield JL, Mannie MD. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC. J Leukoc Biol. 2010;83:509–521.
   Web of Science ®Google Scholar
• Mannie MD, Blanchfield JL, Islam SM, et al. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012;3:255.
   PubMed Web of Science ®Google Scholar
• Mannie MD, Abbott DJ, Blanchfield JL. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-β acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance. J Immunol. 2009;182:5331–5341.
   PubMed Web of Science ®Google Scholar
• Van Monfort T, Melchers M, Isik G, et al. A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T-cell responses. J Biol Chem. 2011;286:22250–22261.
   PubMed Web of Science ®Google Scholar
• Islam SM, Curtis IIAD, Taslim N, et al. GM-CSF-neuroantigen fusion protein reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation dependent, inhibitory antigen presentation. J Immunol. 2014;193:2317–2329.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Alzheimer's disease vaccine development: A new strategy focusing on immune modulation. J Neuroimmunol. 2015;287:54–63.
   PubMed Web of Science ®Google Scholar
• Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen specific immunotherapy. Curr Opin Immunol. 2013;25:410–417.
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995;181:1869–1874.
   PubMed Web of Science ®Google Scholar
• Esensten JH, Helou YA, Chopra G, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973–988.
   PubMed Web of Science ®Google Scholar
• Luo X, Miller SD, Shea LD. Immune tolerance for autoimmune disease and cell transplantation. Annu Rev Biomed Eng. 2016;18:181–205.
   PubMed Web of Science ®Google Scholar
• He S-X, Gershwin ME, Ansari AA. Checkpoint-based immunotherapy for autoimmune diseases: opportunities and challenges. J Autoimmun. 2017;79:1–3.
   PubMed Web of Science ®Google Scholar
• Faria AMC, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006;13:143–157.
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–293.
   PubMed Web of Science ®Google Scholar
• Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol. 2010;40:638–653.
   PubMed Web of Science ®Google Scholar
• Seubert A, Calabro S, Santini L, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA. 2011;108:11169–11174.
   PubMed Web of Science ®Google Scholar
• Weng NP, Akbar AN, Goronzy J. CD28¯ T-cells: their role in the age-associated decline of immune function. Trends Immunol. 2009;30:306–312.
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine. 2008;26:3209–3222.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, et al. The mechanism of action of MF59: an innately attractive adjuvant formulation. Vaccine. 2012;30:4341–4348.
   PubMed Web of Science ®Google Scholar
• Calabro S, Tritto E, Pezzotti A, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 2013;31:3363–3369.
   PubMed Web of Science ®Google Scholar
• Maggio ET. Polysorbates, peroxides, protein aggregation, and immunogenicity – a growing concern. J Excipients and Food Chem. 2012;3:45–53.
   Google Scholar
• Rhodes J, Chen H, Hall SR, et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature. 1995;377:71–75.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934–945.
   PubMed Web of Science ®Google Scholar
• Mahurkar S, Suppiah V, O’Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev. 2014;13:178–186.
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Investig. 2000;105:967–976.
   PubMed Web of Science ®Google Scholar
• Conner J. Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis. J Autoimmun Cell Res. 2014;1:3.
   Google Scholar
• Zheng B, Switzer K, Marinova E, et al. Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity. 2008;41:363–371.
   PubMed Web of Science ®Google Scholar
• Koronyo Y, Salumbides BC, Sheyn J, et al. Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer’s disease. Brain. 2015;138:2399–2422.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. A retrospective analysis of the Alzheimer’s disease vaccine progress: the critical need for new development strategies. J Neurochem. 2016;137:687–700.
   PubMed Web of Science ®Google Scholar
• Garcia-Vallejo JJ, van Kooyk Y. DC-SIGN: The strange case of Dr. Jekyll and Mr. Hyde. Immunity. 2015;42:983–985.
   PubMed Web of Science ®Google Scholar
• Shade K-TC, Anthony RM. Antibody glycosylation and inflammation. Antibodies. 2013;2:392–414.
   Google Scholar
• Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci. 2012;1253:170–180.
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med. 1994;180:1195–1205.
   PubMed Web of Science ®Google Scholar
• Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8.
   PubMedGoogle Scholar
• Van Kooyk Y, Geijtenbeek TBH. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3:697–709.
   PubMed Web of Science ®Google Scholar
• Thomas PG, Carter MR, Atochina O, et al. Maturation of dendritic cell 2 phenotype by a helminth glycan uses a toll-like receptor 4-dependent mechanism. J Immunol. 2003;171:5837–5841.
   PubMed Web of Science ®Google Scholar
• Gringhuis SI, Kaptein TM, Wevers BA, et al. Fucose-specific DC-SIGN signaling directs T helper cell tytpe-2 responses via IKKε- and CYLD-dependent Bcl3 activation. Nat Commun. 2014;5:3898.
   PubMed Web of Science ®Google Scholar
• Kensil CR, Soltysik S, Patel U, et al. Structure/function relationship in adjuvants from Quillaja saponaria Molina. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA, editors. Vaccines 92. New York: Cold Spring Harbor Lab Press; 1992; p. 35–40.
   Google Scholar
• Tso C-L, Zisman A, Pantuck A, et al. Cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-stimulating factor. Cancer Res. 2001;61:7925–7933.
   PubMed Web of Science ®Google Scholar
• Wang Y, Da’Dara AA, Thomas PG, et al. Dendritic cells activated by an anti-inflammatory agent induce CD4+ T helper type 2 responses without impairing CD8+ memory and effector cytotoxic T-lymphocyte responses. Immunology. 2010;129:406–417.
   PubMed Web of Science ®Google Scholar